Atlas Trials

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

Clinical trial NCT07204041 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07204041
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Langerhans Cell Histiocytosis (LCH)
Start date
2025-08-01
Primary completion
2027-08-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.